In vivo glioma mouse model recapitulating key human glioblastoma characteristics provides an invaluable resource to assess novel immunotherapy-based strategies aiming at bolstering immune system functions to ultimately improve treatment outcome.
As in the previous shuttle session, Explicyte will plan a new shuttle on the CT26 tumor-bearing mouse model, which will be held in July.
We designed a specialized in vitro immune cell killing assay to assess your immunomodulatory candidate compounds/antibodies for their ability to enhance the killing immune response towards tumor cells.
To support your R&D program(s) in glioma, Explicyte has validated a syngeneic intracerebral mouse tumor model of Glioblastoma on which gold standard chemotherapy (Temozolomide, TMZ) and immunotherapy (CTLA4) has been validated.
To support your R&D program(s), we propose to explore and characterize the in vitro effect of your candidate compounds on human immune cells.
The Bordeaux-based antibody company ImmuSmol is launching today a range of preclinical services in the field of cancer immunotherapy under the brand Explicyte Immuno-Oncology
To test novel combination therapies aiming at increasing responses rates to immune checkpoint inhibitors, Explicyte has optimized a range of syngeneic mouse tumor models treated with anti-CTLA-4 or anti-PD-1/PD-L1 monoclonal antibodies.
This PLOS ONE paper, co-authored by Alban Bessède, CSO of Explicyte, demonstrates that the expression of tryptophan-degrading enzyme IDO1 is not strictly associated with L-Kynurenine production in breast and colorectal cancer tissues.